-
1.发明公开
公开(公告)号：KR1019990035470A
公开(公告)日：1999-05-15
申请号：KR1019970057273
申请日：1997-10-31
Applicant: 한국과학기술연구원
IPC: C07D307/12 , A61K31/34
Abstract: 본 발명은 화학식 1 및 화학식 2 로 표시되는 새로운 리그난 화합물에 관한 것이다.
또한, 본 발명은 신이 (Magnoliae flos)로부터 화학식 1 및 화학식 2 의 화합물을 제조하는 방법에 관한 것이다.
또한, 본 발명은 새로운 화학식 1 및 화학식 2 의 화합물을 유효 성분으로 하는 혈소판 활성화 인자 (platelet-activating factor, PAF) 수용체에 작용하는 길항제에 관한 것으로서, 이는 상기 혈소판 활성화 인자와 관련된 염증성 질환의 예방 및 치료에 유용하게 사용될 수 있다.
또한, 본 발명은 신이 추출물 및 이를 유효 성분으로 하는 혈소판 활성화 인자 수용체에 작용하는 길항제에 관한 것이다.-
公开(公告)号：KR100302064B1
公开(公告)日：2001-10-26
申请号：KR1019970036988
申请日：1997-08-01
Applicant: 한국과학기술연구원
Abstract: PURPOSE: An antagonist to platelet activating factor(PAF) is provided which is excellent in PAF antagonism, hopeful of displaying excellent effects for improving/preventing various diseases and allergic disorders caused by the PAF antagonism. CONSTITUTION: The platelet activating factor antagonist contains (20s)-ginsenoside Rg3 and/or ginsenoside Rg5 as an effective component. The antagonist can be used for various diseases such as asthma, allergy, arthritis, rheumatism, acute inflammation, anaphylaxis, retinitis, hepatitis, pancreatitis, nephritis, nasal inflammation, atopic dermatitis, cardiac anaphylaxis, endotoxic shock, central nervous system damage or the like. This antagonist also can be used as an auxiliary agent for treatment of inflammation.
-
公开(公告)号：KR1020010086473A
公开(公告)日：2001-09-12
申请号：KR1020010049577
申请日：2001-08-17
Applicant: 한국과학기술연구원
IPC: A61K31/05
Abstract: PURPOSE: Provided is a novel use of essential oil obtained by vapor distillation of plants and showing the inhibitory action against the production of leukotriene as a mediator of inflammation. CONSTITUTION: An inhibitor of leukotriene production comprises at least a compound selected from the group consisting of (-)-menthol, (+)-limonene, alpha-terpinene, gamma-terpinene, terpineol, beta-myrcene, (±)-linaloo, geraniol, citral, beta-cyclocitral, eugenol, safrole, (+)-alpha-pinene, (-)-alpha-pinene, and (+)-cis-verbenol, as an effective components. Preferably, the inhibitor comprises eugenol or safrole as an active ingredient. The inhibitor can be used for a variety of inflammatory diseases including asthma, whooping cough, psoriasis, arthritis, inflammatory intestine diseases, cystic fibrosis, chronic bronchitis, rheumatoid arthritis, septic shock, myocardial ischemia, cardiac anaphylaxis, cerebral vasospasm, ischemia and allergic rhinitis.
Abstract translation: 目的：提供通过蒸汽蒸馏植物获得的精油的新用途，并显示出作为炎症介质产生白三烯的抑制作用。 构型：白三烯生产抑制剂包括至少一种选自（ - ） - 薄荷醇，（+） - 柠檬烯，α-萜品烯，γ-萜品烯，萜品醇，β-月桂烯，（±）-Linaloo， 香叶醇，柠檬醛，β-环萜烯，丁子香酚，黄樟脑，（+） - 蒎烯，（ - ） - 蒎烯和（+） - 顺式 - 马鞭草醇作为有效成分。 优选地，抑制剂包括丁子香酚或黄樟脑作为活性成分。 抑制剂可用于各种炎性疾病，包括哮喘，百日咳，牛皮癣，关节炎，炎性肠病，囊性纤维化，慢性支气管炎，类风湿性关节炎，败血性休克，心肌缺血，心脏过敏反应，脑血管痉挛，局部缺血和过敏性鼻炎 。
-
4.发明授权신이로부터분리한새로운리그난화합물,그의제조방법및이를유효성분으로하는혈소판활성화인자수용체에작용하는길항제 有权新型Lignan化合物，从MAGNOLIAE FLOS制备的方法和用于平板激活因子受体拮抗剂的方法
公开(公告)号：KR100263439B1
公开(公告)日：2000-08-01
申请号：KR1019970057273
申请日：1997-10-31
Applicant: 한국과학기술연구원
IPC: C07D307/12 , A61K31/34
Abstract: PURPOSE: A lignan compound separated from Magnoliae flos is provided, which is useful in manufacturing platelet-activating factor and preventing and treating inflammatory diseases. And its manufacturing method is also provided. CONSTITUTION: The method for separating compounds of the formula (1) and (2) is comprised of the next steps of: i) mashing 3kg of Magnoliae flos and obtaining extracts using methanol; ii) condensing the extracts; iii) suspending the extracts in distilled water and obtaining ethylacetate; iv) obtaining the two compounds from ethylacetate by silica gel column chromatography. The compound of the formula (1) has no color, and molecular weight of 402. And its molecular formula is C22H26O7. The compound of the formula (2) has no color and molecular weight of 432 and its molecular formula is C23H28O8.
Abstract translation: 目的：提供从Magnoliae flos分离的木脂素化合物，可用于制造血小板活化因子和预防和治疗炎症性疾病。 并提供其制造方法。 构成：分离式（1）和（2）化合物的方法包括以下步骤：i）将3kg Magnoliae flos糖化并用甲醇获得提取物; ii）冷凝提取物; iii）将提取物悬浮在蒸馏水中并获得乙酸乙酯; iv）通过硅胶柱色谱从乙酸乙酯中得到两种化合物。 式（1）的化合物没有颜色，分子量为402.分子式为C22H26O7。 式（2）的化合物的颜色和分子量为432，分子式为C 23 H 28 O 8。
-
公开(公告)号：KR1020000026052A
公开(公告)日：2000-05-06
申请号：KR1019980043424
申请日：1998-10-17
Applicant: 한국과학기술연구원
CPC classification number: A61K36/57 , A61K31/34 , A61K2236/33 , A61K2236/51
Abstract: PURPOSE: A lignan compound isolated from magnolia floss or extract of magnolia floss having excellent anti-asthma efficacy is provided, which can be used as a preventing agent, a medicine or a treatment assistance for asthma. CONSTITUTION: A lignan compound like as pinoresinol dimethyl ether of formula 1, mandolin of formula 2, liroresinol-B-dimethyl ether of formula 3 and (+)-epimandolin A is gained by the process of: extracting from magnolia bud using primary alcohol like as methanol; concentrating and adding distilled water and hexane; isolating hexane layer; concentrating and adding ethylacetate; isolating ethylacetate layer; concentrating and separating using silicagel column chromatography.
Abstract translation: 目的：提供从木兰中分离的木酚素化合物或具有优异抗哮喘功效的木兰提取物，可用作预防剂，药物或哮喘治疗辅助用途。 构成：通过以下方法获得如式1的膦酰基二醇二甲醚，式2的曼陀罗，式3的双酚基-β-二甲醚和（+） - 依马久灵A的木脂素化合物：使用伯醇 作为甲醇; 浓缩并加入蒸馏水和己烷; 分离己烷层; 浓缩并加入乙酸乙酯; 分离乙酸乙酯层; 使用硅胶柱色谱法浓缩和分离。
-
Patent Agency Ranking6.发明公开
-
公开(公告)号：KR1019980045814A
公开(公告)日：1998-09-15
申请号：KR1019960064025
申请日：1996-12-10
Applicant: 한국과학기술연구원
IPC: A61K31/575 , C07J9/00
Abstract: 본 발명은 하기 화학식 1 의 사이트로스테디엔올 [citrostadienol,(3β,4α,5α,24Z)-4-메틸스티그마스타-7,24(28)-디엔-3-올]을 보체계의 비정상적인 활성화로 유발되는 염증을 효과적으로 억제하는 보체 활성 조절제 (anti- complementarity drug)로 사용하는 용도, 이를 오미자 (
Schizandrae fructus )로부터 분리하는 제조방법 및 보체 활성을 조절하는 오미자 추출물에 관한 것으로서, 본 발명의 사이트로스테디엔올 및 오미자 추출물은 천식, 알레르기, 관절염, 류마치스, 전신성 홍반성 난창, 망막염, 간염 및 비염 등의 염증 질환에 유용하게 사용될 수 있다.
[화학식 1]-
公开(公告)号：KR100370884B1
公开(公告)日：2003-12-01
申请号：KR1019980022501
申请日：1998-06-16
Applicant: 한국과학기술연구원
IPC: C07H21/00
Abstract: PURPOSE: A compound, tylinoside, having an anticomplement activity is isolated from Magnolia flos and the structure thereof is examined by spectroscopy. CONSTITUTION: Tylinoside of formula (I) is isolated from Magnolia floes and the pharmaceutical composition, containing the isolated compound of formula (I) as an effective ingredient of complement activity regulating agent, is prepared. Thus, Magnolia flos is crushed and extracted with methanol and the filtrated liquid is vacuum concentrated, suspended in distilled water, and extracted with ethylacetate. The extracts are fractionated with silica gel column chromatography to isolate the tylinoside of formula (I).
Abstract translation: 目的：从Magnolia flos分离具有抗补体活性的化合物，tylinoside，并通过光谱检查其结构。 构成：从Magnolia絮凝物中分离式（I）的Tylinoside，并制备含有分离的式（I）化合物作为补体活性调节剂的有效成分的药物组合物。 因此，将白玉兰花粉碎并用甲醇萃取，将过滤的液体真空浓缩，悬浮于蒸馏水中，并用乙酸乙酯萃取。 将提取物用硅胶柱色谱分离以分离式（I）的泰瑞诺苷。
-
公开(公告)号：KR100328478B1
公开(公告)日：2002-09-04
申请号：KR1019980043424
申请日：1998-10-17
Applicant: 한국과학기술연구원
Abstract: 본 발명은 항천식 효능을 가지는 신이 (
Magnoliae flos ) 추출물 및 신이로부터 분리한 리그난 화합물에 관한 것으로, 신이를 유기용매로 추출하여 얻어지는 본 발명의 신이 추출물 및 이로부터 분리되는 하기 화학식 1 내지 화학식 4의 리그난 화합물은 천식의 예방제, 치료제 및 치료보조제를 비롯한 항천식 효능제로 유용하게 사용될 수 있다.
[화학식 1]
[화학식 2]
[화학식 3]-
公开(公告)号：KR100302063B1
公开(公告)日：2001-10-26
申请号：KR1019970036989
申请日：1997-08-01
Applicant: 한국과학기술연구원
IPC: A61K31/575 , A61P37/00
Abstract: PURPOSE: A complement activity controlling agent containing at least one of ginseng saponin or sapogenin compounds capable of being produced by extracting, separating or purifying ginseng or red ginseng and a therapeutic agent associated with complement activity is provided which can be effectively used for treatment of various diseases such as asthma, allergy, atopic dermatitis or the like. CONSTITUTION: The complement activity-controlling agent contains at least one of ginseng saponin or sapogenin compounds represented by the formula 1. The saponin or sapogenin compounds are ginsenoside Ra1, ginsenoside Ra2, ginsenoside Rb1, ginsenoside Rb2, ginsenoside Rc, ginsenoside Rd, ginsenoside Re, ginsenoside Rf, ginsenoside Rg1, ginsenoside Rg2, ginsenoside Rh1, ginsenoside Rh2, ginsenoside Rh4, ginsenoside R0 and olenolic acid.
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.023 seconds)
